Targeted Fgfr Blockade For The Treatment of Tumor-Induced Osteomalacia

Authors

Iris R Hartley
Carole B Miller
Georgios Z Papadakis
Clemens Bergwitz
Jaydira Del Rivero
Jenny E Blau
Pablo Florenzano
Jason A Berglund
Jing Tassone
Kelly L Roszko
Susan Moran
Rachel I Gafni
Randi Isaacs
Michael T Collins

Publication Date

10-1-2020

Journal

New England Journal of Medicine

Keywords

Aged, Chondrosarcoma, Mesenchymal, Disease Progression, Fatal Outcome, Fibroblast Growth Factor-23, Fibroblast Growth Factors, Humans, Male, Molecular Targeted Therapy, Neoplasms, Connective Tissue, Osteomalacia, Paraneoplastic Syndromes, Phenylurea Compounds, Positron Emission Tomography Computed Tomography, Pyrimidines, Receptor Protein-Tyrosine Kinases, Receptor, Fibroblast Growth Factor, Type 1

DOI

10.1056/NEJMc2020399

PMID

32905668

PMCID

PMC7561341

PubMedCentral® Posted Date

April 2021

PubMedCentral® Full Text Version

Author MSS

Recommended Citation

Hartley, Iris R; Miller, Carole B; Papadakis, Georgios Z; Bergwitz, Clemens; Del Rivero, Jaydira; Blau, Jenny E; Florenzano, Pablo; Berglund, Jason A; Tassone, Jing; Roszko, Kelly L; Moran, Susan; Gafni, Rachel I; Isaacs, Randi; and Collins, Michael T, "Targeted Fgfr Blockade For The Treatment of Tumor-Induced Osteomalacia" (2020). Faculty, Staff and Student Publications. 46.
https://digitalcommons.library.tmc.edu/uthdb_docs/46